General Information of Drug (ID: DMJ02RH)

Drug Name
AT-177 Drug Info
Indication
Disease Entry ICD 11 Status REF
Ulcerative colitis DD71 Clinical trial [1]
Cross-matching ID
TTD Drug ID
DMJ02RH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [2]
Tapinarof DMRPI2Q Plaque psoriasis EA90.0 Approved [3]
RVT-505 DM3C9F8 Atopic dermatitis EA80 Phase 2 [4]
IK-175 DMDU54Y Urothelial carcinoma 2C92.0 Phase 1 [5]
BAY 2416964 DMD9N12 Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
CB7993113 DMJUQ6E Solid tumour/cancer 2A00-2F9Z Preclinical [7]
2-(1H-indole-3,-carbonyl)-thiazole-4-carboxylic acid methyl ester DMIS1G7 Glioma 2A00.0 Preclinical [8]
6-Formylindolo[3,2-b]carbazole DMN84RM Dermatitis EA80-EA89 Investigative [9]
CH-223191 DMMJZYC Solid tumour/cancer 2A00-2F9Z Investigative [10]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aryl hydrocarbon receptor (AHR) TT037IE AHR_HUMAN Agonist [1]

References

1 Clinical pipeline report, company report or official report of Azora Therapeutics
2 A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer. 2005 Oct 17;93(8):876-83.
3 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215272.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of Ikena Oncology.
6 ClinicalTrials.gov (NCT04069026) A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer. U.S. National Institutes of Health.
7 In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo. Mol Pharmacol. 2014 Nov;86(5):593-608.
8 1'H-Indole-3'-Carbonyl-Thiazole-4-Carboxylic Acid Methyl Ester Blocked Human Glioma Cell Invasion via Aryl Hydrocarbon Receptor's Regulation of Cytoskeletal Contraction. Biomed Res Int. 2020 Oct 3;2020:2616930.
9 6-Formylindolo(3,2-b)carbazole induced aryl hydrocarbon receptor activation prevents intestinal barrier dysfunction through regulation of claudin-2 expression. Chem Biol Interact. 2018 May 25;288:83-90.
10 Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. Mol Pharmacol. 2006 Jun;69(6):1871-8.